ADD/ADHD News

Most children in the United States with attention-deficit/hyperactivity disorder were diagnosed by their primary care providers, regardless of age at diagnosis, according to a CDC report.

The risk for attention-deficit/hyperactivity disorder was greater among preterm infants and infants with poor fetal growth, according to recent research published in Pediatrics.

Young adults diagnosed with attention deficit/hyperactivity disorder in adolescence exhibited structural and functional deficits associated with abnormal working memory function, suggesting changes in the brain may persist into adulthood despite clinical improvement.

Adults who sustained a traumatic brain injury were significantly more likely to screen for or be diagnosed with attention-deficit/hyperactivity disorder during their lifetime, according to study findings in the Journal of Psychiatric Research.

As the month of August comes to a close and the beginning of the school year approaches, it may be the perfect time to revisit the latest research, treatment approvals and guidance associated with attention-deficit/hyperactivity disorder.

Children with attention-deficit/hyperactivity disorder exhibited greater improvement in cognitive task performance with reinforcement because of higher trait sensitivity to reward, not because of poorer performance in cognitive functioning at baseline.

Mothers with chemical intolerance are more likely to give birth to children with attention-deficit/hyperactivity disorder or autism spectrum disorder, according to a recent study.

According to a recent study, pediatric patients with long QT syndrome who also were treated with attention-deficit/hyperactivity disorder medications were at an increased risk for cardiac events.

Individuals with psychiatric problems in childhood were more likely to have problems functioning in adulthood, according to study findings in JAMA Psychiatry.

Amphetamine sulfate was effective and well-tolerated among children with attention-deficit/hyperactivity disorder, with an effect onset of 45 minutes that continued through 10 hours post-dosing, according to results from a dose-optimized, double-blind, randomized, placebo-controlled, crossover laboratory classroom study.